Tumor-targeting and tumor-penetrating peptide enables EnduRx Pharmaceuticals novel prodrug for triple-negative breast cancerContinue reading
Category Archives: AZBio News
Governor Ducey Takes Further Action To Reverse COVID-19 Spread In Arizona
Large Gatherings Suspended; Bars, Gyms, Movie Theaters, Waterparks and Tubing Rentals Must Pause Operations; School Restart DelayedContinue reading
Cancer Prevention Pharmaceuticals Submits New Drug Application to the FDA for CPP-1X/sul for Treatment of Familial Adenomatous Polyposis
Company seeks accelerated approval for cancer drug
TUCSON, Arizona, June 29, 2020 – Cancer Prevention Pharmaceuticals, Inc. (CPP), a private biotech company developing novel therapeutics to prevent cancer and other diseases, announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking accelerated approval for CPP-1X/sul for treatment of adults with familial adenomatous polyposis (FAP).Continue reading
Gilead Announces Pricing for Remdesivir in Open Letter
According to Daniel O’Day, Chairman & CEO, Gilead Sciences, “In the U.S., the same government price of $390 per vial will apply. Because of the way the U.S. system is set up and the discounts that government healthcare programs expect, the price for U.S. private insurance companies, will be $520 per vial. At the level we have priced remdesivir and with government programs in place, along with additional Gilead assistance as needed, we believe all patients will have access.”
FDA Approves First-Of-Its-Kind Percept™ PC Neurostimulator with BrainSense™ Technology
Next-Generation Technology Makes Percept™ the First and Only DBS System with Ability to Capture Patient-Specific Brain Signals
for More Personalized, Data-Driven TreatmentContinue reading
Dr. Joann Sweasy Named Director of University of Arizona Cancer Center
Dr. Sweasy will serve as director of the only Arizona-based National Cancer Institute-designated Comprehensive Cancer Center, as well as UArizona’s chief adviser on cancer-related matters and principal investigator of the NCI Cancer Center Support Grant.Continue reading
The MedTech Conference to Go Virtual for 2020
“The show will go on!” says AdvaMed CEO Scott WhitakerContinue reading
C-Path Launches CURE Drug Repurposing Collaboratory to Accelerate Identification of New Uses of Existing Drugs to Treat Infectious Diseases, Including COVID-19
Clinicians to report novel uses of existing drugs through FDA-NCATS CURE ID Mobile App.
TUCSON, Ariz., June 23, 2020 — As millions of patients struggle with diseases that lack adequate treatments, there is a critical need to understand how existing drugs can be used in new ways to improve clinical outcomes. Health care professionals use drugs in novel ways as a potential life-saving intervention when no specific approved therapies are available. However, without the ability to share these experiences in a systematic manner, the clinical and research communities cannot benefit from lessons learned.Continue reading
NIH halts clinical trial of hydroxychloroquine
Study shows treatment does no harm, but provides no benefitContinue reading
HTG Introduces the HTG EdgeSeq Pan B-Cell Lymphoma Panel
Comprehensive Panel Designed to Provide Molecular Characterization of Aggressive LymphomasContinue reading